Haemonetics splits with Zimmer
This article was originally published in The Gray Sheet
Executive Summary
Haemonetics Corp. will end its five-year U.S. distribution agreement with Zimmer for the OrthoPAT blood management system, the company announces Aug. 30. Haemonetics, which already sells OrthoPAT directly in Europe and Asia, will expand its sales and services operations to accommodate the extended U.S. customer base once Zimmer's distribution rights end in February 2006. Zimmer will pursue internal and external development of new blood salvage technologies...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.